Mirna Therapeutics Raises $34.5M

Austin-based Mirna Therapeutics, which is developing microRNA-based therapeutics for treating cancer, has raised $34.5M in a Series C funding round. The firm said the funding was led by Sofinnova Ventures, and also included New Enterprise Associates (NEA), Pfizer Ventures, Osage University Partners, Correlation Ventures, along with existing investors. Michael Powell of Sofinnova, Ed mathers of NEA, and Elaine Jones of Pfizer will join the company's board with the funding. miRNA has previously raised funding from the Texas Emerging Technology Fund (TETF) and the Cancer Prevention and Research Institute of Texas (CPRIT). More information »